-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

The Case for MRD Testing and the Relevance to Treatment Decisions and Outcomes in AML.

Program: How I Treat: Bringing Science to Clinical Dilemmas
Hematology Disease Topics & Pathways:
AML, Acute Myeloid Malignancies, Diseases, Myeloid Malignancies, Minimal Residual Disease
Saturday, December 10, 2022: 8:00 AM-9:00 AM
Canal (Hilton New Orleans Riverside)
Christopher S. Hourigan, MD, National Heart, Lung, and Blood Institute, National Institutes of Health
No relevant conflicts of interest to declare.